loading page

Targeting PPARα/γ by icariside Ⅱ to rescue acute liver injury via coactivating SIRT6
  • +6
  • Jianmei Gao,
  • Jiajia Wei,
  • Yang Yi,
  • Miaoxian Gong,
  • Fangqin Hou,
  • Xiaoyu Wu,
  • Yiqi Li,
  • Yuandong Zhang,
  • Qihai Gong
Jianmei Gao
Zunyi Medical University
Author Profile
Jiajia Wei
Zunyi Medical University
Author Profile
Yang Yi
Zunyi Medical University
Author Profile
Miaoxian Gong
Zunyi Medical University
Author Profile
Fangqin Hou
Zunyi Medical University
Author Profile
Xiaoyu Wu
Zunyi Medical University
Author Profile
Yiqi Li
Zunyi Medical University
Author Profile
Yuandong Zhang
Zunyi Medical University
Author Profile
Qihai Gong
Zunyi Medical University

Corresponding Author:875705575@qq.com

Author Profile

Abstract

Background and Purpose:: Peroxisome proliferator-activated receptor α and-γ (PPARα/γ) are known to play crucial roles in acute liver injury (ALI). Icariside Ⅱ (ICS Ⅱ), a natural flavonoid compound derived from Herba Epimedii, confers neuroprotection with PPARα/γ induction potency. This study was aimed to explore whether ICS Ⅱ has the capacity to protect against ALI, and if so what are the role of PPARα/γ in the beneficial effect of ICS Ⅱ on ALI. Experimental Approach: Mice challenged by D-galactosamine (GalN)/lipopolysaccharide (LPS) and Kupffer cells (KCs) upon LPS insult were used as ALI models in vivo and in vitro. PPARα/γ-deficient mice and Sirt6-deficient mice were treated with ICS Ⅱ to validate the potential targets of ICS Ⅱ on ALI. Key results: ICS Ⅱ dose-dependently improved the survival rate and liver histology, decreased ALT and AST in D-galactosamine (GalN)/lipopolysaccharide (LPS)-treated mice. Furthermore, ICS Ⅱ directly bound to PPARα/γ and increased their activities. The protective properties of ICS Ⅱ were counteracted when PPARα/γ were knocked out in GalN/LPS-induced mice and LPS-induced KCs, respectively. Mechanistically, ICS Ⅱ restored mitochondrial function, reduced oxidative stress and inflammation through activating PPARα/γ, which interacted with Sirt6 and inhibited NF-κB nuclear translocation. Intriguingly, ICS Ⅱ-evoked hepatoprotective effect and activation of PPARα/γ were largely blunted in Sirt6-deficient mice. Conclusions and implications: Our findings not only highlight PPARα/γ-SIRT6 signaling as a vital therapeutic target to combat ALI, but also reveal ICS Ⅱ may serve as a novel dual PPARα/γ agonist to safeguard ALI from the oxidation-inflammation vicious circle by coactivating SIRT6.